CompletedPhase 3NCT00943306
Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
Studying Rare hypercholesterolemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Aegerion Pharmaceuticals, Inc.
- Principal Investigator
- Marina Cuchel, MD, PhDUniversity of Pennsylvania
- Intervention
- lomitapide(drug)
- Enrollment
- 19 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2014
Study locations (10)
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Robarts Research Institute, London, Ontario, Canada
- Lipid Clinic and University of Montreal Community Genomic Medicine Center, Chicoutimi, Quebec, Canada
- Medicina Interna Universitaria, Ferrara, Sicily, Italy
- Dipartimento di Medicina Clinica e Delle Patologie Emergenti, Palermo, Sicily, Italy
- Centro Universitario Dislipidemie, Milan, Italy
- DAI Ematologia, Oncologia, Anatomia Patologica e Medicina, Roma, Italy
- Cardiology Research, Bloemfontein, South Africa
- University of Capetown, Cape Town, South Africa
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00943306 on ClinicalTrials.govOther trials for Rare hypercholesterolemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07470723The ORIGIN-FH StudyUniversity of Wisconsin, Madison
- RECRUITINGNANCT06960902Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)Nantes University Hospital
- RECRUITINGPHASE2, PHASE3NCT07058077A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)Merck Sharp & Dohme LLC
- RECRUITINGNCT06958315Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE StudyNovartis Pharmaceuticals
- RECRUITINGNCT04529967Child-Parent Familial Hypercholesterolemia ScreeningChildren's Hospital of Fudan University
- RECRUITINGPHASE3NCT06597006Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaNovartis Pharmaceuticals
- RECRUITINGNCT06634160Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial HypercholesterolemiaNantes University Hospital
- RECRUITINGPHASE3NCT06597019Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaNovartis Pharmaceuticals